Tci (8436) reported revenue of NT$508.3 million for Oct 2026, -19.4% year on year and -2.4% from the previous month. Revenue for Jan–Oct 2026 was NT$5.44 billion (-5.4% year on year).
In Oct 2026, it ranked No. 17 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$508.3 million | -19.4% | -2.4% |
| Sep 2026 | NT$520.7 million | -16.1% | -4.6% |
| Aug 2026 | NT$545.6 million | +2.0% | +6.3% |
| Jul 2026 | NT$513.3 million | -12.2% | -14.9% |
| Jun 2026 | NT$603 million | -14.6% | +19.5% |
| May 2026 | NT$504.6 million | -9.7% | -16.7% |
| Apr 2026 | NT$605.5 million | +14.0% | -0.9% |
| Mar 2026 | NT$611 million | +0.2% | +42.3% |
| Feb 2026 | NT$429.5 million | -2.8% | -28.5% |
| Jan 2026 | NT$600.6 million | +12.2% | -20.9% |
| Dec 2025 | NT$758.8 million | +18.2% | +59.2% |
| Nov 2025 | NT$476.6 million | -24.8% | -24.4% |
| Oct 2025 | NT$630.7 million | -5.9% | +1.6% |
| Sep 2025 | NT$620.8 million | -4.7% | +16.1% |
| Aug 2025 | NT$534.7 million | +0.4% | -8.5% |
| Jul 2025 | NT$584.6 million | -5.8% | -17.2% |
| Jun 2025 | NT$706 million | +17.4% | +26.3% |
| May 2025 | NT$559.1 million | -21.4% | +5.3% |
| Apr 2025 | NT$531.1 million | -20.1% | -12.9% |
| Mar 2025 | NT$609.6 million | +12.6% | +37.9% |
| Feb 2025 | NT$442.1 million | +14.0% | -17.4% |
| Jan 2025 | NT$535.2 million | -8.2% | -16.7% |
| Dec 2024 | NT$642.2 million | -1.8% | +1.3% |
| Nov 2024 | NT$633.8 million | -1.2% | -5.5% |
| Oct 2024 | NT$670.4 million | +0.1% | +2.9% |
Jan–Oct 2026 cumulative: NT$5.44 billion (-5.4% YoY)
Other Biotech & Medical companies
Compare with peers: Tci vs PEC / Tci vs Lotus Pharm / Tci vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16